Novo Nordisk CEO and Board Leadership Step Down Amid Market Pressures; New Board to Prioritize Faster Decision-Making

Novo Nordisk; CEO resignation; Lars Fruergaard Jørgensen; board leadership change; Novo Nordisk Foundation; share price decline; strategic decision-making; competition; Lars Rebien Sørensen; executive transition

Strategic Acquisition, Partnership, and Development of Innovative Assets in Biopharma

Biopharma, Innovative Assets, Acquisition, Partnership, Development, Strategic Decision-Making, Pharmaceutical Industry, Drug Development, Market Trends, Risk Management, Portfolio Diversification